Drug Utilization in Patients with Polyarticular Juvenile Idiopathic Arthritis (pJIA): A Descriptive Analysis

In this request, we examined characteristics of patients with a diagnosis of polyarticular Juvenile Idiopathic Arthritis (pJIA) and utilization of tocilizumab, abatacept, adalimumab and etanercept, in the Merative™ MarketScan® Research Databases between October 1, 2015 and March 31, 2019. We executed this request on September 10, 2020. This analysis consists of two reports: 

• Report 1: This report specified a pre-index enrollment period of 365 days for all cohorts.
• Report 2: This report modified the pre-index enrollment period to 183 days.